Top

Published in:

01-02-2013 | Original Article

Transurethral intraprostatic Botulinum toxin-A injection: a novel treatment for BPH refractory to current medical therapy in poor surgical candidates

Authors: Ali Hamidi Madani, Ahmad Enshaei, Abtin Heidarzadeh, Gholamreza Mokhtari, Alireza Farzan, Mani Mohiti Asli, Samaneh Esmaeili

Published in: World Journal of Urology | Issue 1/2013

Abstract

Purpose

Benign prostatic hyperplasia (BPH) is the main cause of lower urinary tract symptoms (LUTS) in elderly men. Some patients respond poorly to routine medical therapy and are not well suited for surgery, too. This study was planned to evaluate the effect of Botulinum-A on BPH refractory to current medical therapy in poor surgical candidates.

Methods

In this clinical trial, 10 patients with LUTS suggestive of BPH who had responded poorly to medical therapy for at least 6 months and were poor surgical candidates, were received different doses of transurethral Botulinum-A injection based on their prostate volume. The prostate volume, PSA, Qmax, IPSS, PVR and frequency of nocturia were evaluated and compared before and after treatment.

Results

The mean IPSS was 24.50 ± 3.8 and 13.40 ± 2.67 before and after the treatment, respectively (P < 0.001). The mean prostate volume was decreased from 41.50 ± 10.85 mL to 30.40 ± 8.05 mL (P < 0.001). The Qmax was increased from 7.87 ± 2.01 mL/s to 16.19 ± 1.76 mL/s (P < 0.001). The mean PSA was 3.12 ± 0.49 ng/mL and 1.71 ± 0.39 ng/mL before and after treatment, respectively (P < 0.001). The mean PVR was 75.6 ± 51.63 mL and 63.50 ± 36.59 mL before and after treatment, respectively (P = 0.096). The mean number of nocturia was decreased from 4.1 ± 0.87 to 2.4 ± 0.84 (P < 0.001). The mean IPSS, Prostate volume, PSA and frequency of nocturia were decreased significantly. Although mean PVR was decreased but it wasn’t statistically significant. The mean Qmax was increased significantly.

Conclusion

Intraprostatic injection of Botulinum-A may be an effective and safe treatment for symptomatic BPH in selected patients whose medical treatment has faced failure and are poor surgical candidates. Transurethral method could be selected as a preferable technique of injection.

Walsh PC (1996) Treatment of B.P.H. N Engl J Med 335:557–563

Lepor H (1998) The pathophysiology of lower urinary tract symptoms in the ageing male population. Br J Urol 81:29–33PubMed

McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL et al (1998) The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride long-term efficacy and safety study group. N Engl J Med 338:557–563PubMedCrossRef

Lepor H, Williford WO, Barry MJ, Brawer MK, Dixon CM, Gormley G et al (1996) The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans affairs cooperative studies benign prostatic hyperplasia study group. N Engl J Med 335:533–539PubMedCrossRef

Kuo HC (2005) Prostatic Botulinum A toxin injection- an alternative for benign prostatic obstruction in poor surgical candidates. Urology 65:670–674PubMedCrossRef

AUA practice guidelines committee (2003) AUA guideline on management of benign prostatic hyperplasia, Chap. 1, diagnosis and treatment recommendations. J Urol 2003(170):530–547

Smith CP, Chancellor MB (2004) Emerging role of botulinium toxin in the treatment of voiding dysfunction. J Urol 171(6 Pt 1):2128–2137PubMedCrossRef

Aoki KR (2001) A comparison of the safety margin of Botulinum neurotoxin serotypes A, B, and F in mice. Toxicon 39:1815

Hc Kuo (2003) Effect of Botulinium A toxin in the treatment of voiding dysfunctiom due to detrusor overactivity. Urology 61:550–554CrossRef

10.

Barry MJ, Roehrborn CG (2001) Benign prostatic hyperplasia. BMJ 323:1042–1046PubMedCrossRef

11.

Andersen JT, Nickel JC, Marshall VR, Schulman CC, Boyle P (1997) Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia. Urology 49:839–845PubMedCrossRef

12.

Rapp DE, Turk KW, Bales GT, Cook SP (2006) Botulinum toxin type a inhibits calcitonin gene-related peptide release from isolated rat bladder. J Urol 175(3 Pt 1):1138–1142PubMedCrossRef

13.

Duggan MJ, Quinn CP, Chaddock JA, Purkiss JR, Alexander FC, Doward S et al (2002) Inhibition of release of neurotransmitters from rat dorsal root ganglia by a novel conjugate of a Clostridium Botulinum toxin A endopeptidase fragment and Erythrina cristagalli lectin. J Biol Chem 227:34846–34852CrossRef

14.

Morenilla-Palao C, Planells-Cases R, García-Sanz N, Ferrer-Montiel A (2004) Regulated exocytosis contributes to protein kinase C potentiation of vanilloid receptor activity. J Biol Chem 279:25665–25672PubMedCrossRef

15.

Dinis P, Charrua A, Avelino A, Nagy I, Quintas J, Ribau U, Cruz F (2005) The distribution of sensory fibers immunoreactive for the TRPV1 (capsaicin) receptor in the human prostate. Eur Urol 48:162–167PubMedCrossRef

16.

Silva J, Silva C, Saraiva L, Silva A, Pinto R, Dinis P, Cruz F (2000) Intraprostatic Botulinum toxin type A Injection in patients unfit for surgery presenting with refractory urinary retention and benign prostatic enlargement effect on prostate volume and micturition resumption. Eur Urol 53:153–159CrossRef

17.

Oeconomou A, Madersbacher H, Kiss G, Berger TJ, Melekos M, Rehder P (2008) Is Botulinum neurotoxin type A (BoNT-A) a novel therapy for lower urinary tract symptoms due to benign prostatic enlargement? A review of the literature. Eur Urol 54:765–775PubMedCrossRef

18.

Chuang YC, Huang CC, Kang HY, Chiang PH, Demiguel F, Yoshimura N, Chancellor MB (2000) Novel action of Botulinum toxin on the stromal stromal and epithelial components of the prostate gland. J Urol 175(3 Pt 1):1158–1163

19.

Lin AT, Yang AH, Chen KK (2007) Effects of Botulinum toxin A on the contractile function of dog prostate. Eur Urol 52:582–589PubMedCrossRef

20.

Ventura S, Pennefather JN, Mitchelson F (2002) Cholinergic innervation and function in the prostate gland. Pharmacol Ther 94:93–112PubMedCrossRef

21.

Doggweiler R, Zermann DH, Ishigooka M, Schmidt RA (1998) Botox induced prostatic involution. Prostate 37:44–50PubMedCrossRef

22.

Smith CP, Franks ME, McNeil BK, Ghosh R, de Groat WC, Chancellor MB, Somogyi GT (2003) Effect of botulinum toxin A on the autonomic nervous system of the rat lower urinary tract. J Urol 169:1896–1900PubMedCrossRef

23.

Chuang YC, Chiang PH, Huang CC, Yoshimura N, Chancellor MB (2005) Botulinum toxin type A improves benign prostatic hyperplasia symptoms in patients with small prostates. Urology 66:775–779PubMedCrossRef

24.

Maria G, Brisinda G, Civello IM, Bentivoglio AR, Sganga G, Albanese A (2003) Relief by Botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology 62:259–264PubMedCrossRef

25.

Guercini F, Giannantoni A, Bard RL, Brisinda G, Cadeddu F, Maria G et al (2005) Intraprostatic botulin toxin injection in patients with severe benign prostatic hyperplasia a multicenter feasibility study. J Urol 173(suppl.):376–377

26.

Chuang YC, Chancellor MB (2006) The application of Botulinium Toxin in the prostate. J Urol 176:2375–2382PubMedCrossRef

Title: Transurethral intraprostatic Botulinum toxin-A injection: a novel treatment for BPH refractory to current medical therapy in poor surgical candidates
Authors: Ali Hamidi Madani
Ahmad Enshaei
Abtin Heidarzadeh
Gholamreza Mokhtari
Alireza Farzan
Mani Mohiti Asli
Samaneh Esmaeili
Publication date: 01-02-2013
Publisher: Springer-Verlag
Published in: World Journal of Urology / Issue 1/2013
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-012-0851-z

2024 ASCO Annual Meeting

Springer Medicine

Transurethral intraprostatic Botulinum toxin-A injection: a novel treatment for BPH refractory to current medical therapy in poor surgical candidates

Abstract

Purpose

Methods

Results

Conclusion

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2013

Mapping the cytokine profile of painful bladder syndrome/interstitial cystitis in human bladder and urine specimens

Distinct patterns and behaviour of urothelial carcinoma with respect to anatomical location: how molecular biomarkers can augment clinico-pathological predictors in upper urinary tract tumours

Oncologic outcomes obtained after neoadjuvant and adjuvant chemotherapy for the treatment of urothelial carcinomas of the upper urinary tract: a review

Significance of ADC value for detection and characterization of urothelial carcinoma of upper urinary tract using diffusion-weighted MRI

Brain penetration of the OAB drug trospium chloride is not increased in aged mice

The oncologic impact of a delay between diagnosis and radical nephroureterectomy due to diagnostic ureteroscopy in upper urinary tract urothelial carcinomas: results from a large collaborative database